Natriumbicarbonat Fresenius (Sodium Hydrogen Carbonate)

Sodium bicarbonate dissociates into bicarbonate ions that bind excess hydrogen ions, forming carbonic acid which quickly converts to water and carbon dioxide. This buffering raises blood pH, reduces acidity, and promotes the shift of potassium into cells, helping to restore normal acid‑base balance.

The dose is individualized and determined by the prescribing clinician based on the patient’s arterial pH, bicarbonate level, body weight, and the severity of the underlying condition. No fixed regimen is provided in this description.

The pregnancy safety category for sodium bicarbonate injection is not clearly defined. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with oral sodium bicarbonate, the injectable form provides rapid systemic alkalinization and precise control in acute settings. Unlike potassium‑based alkalizers, it does not add potassium load, making it preferable when hyperkalemia is a concern. Choice depends on clinical urgency, patient renal function and electrolyte status.

Store the solution at controlled room temperature, typically below 25 °C, in its original packaging. Protect from light, moisture and extreme temperature fluctuations. Do not freeze the product and inspect the vial for particulate matter before use.

The product is administered intravenously by slow infusion through a sterile line. The infusion rate is adjusted according to the patient’s acid‑base status and cardiovascular tolerance, and the solution is mixed with compatible diluents as directed by the prescribing information.

Serious adverse events include metabolic alkalosis, severe hypernatremia that can cause neurological symptoms, and pulmonary edema due to fluid overload. Continuous monitoring of arterial blood gases, electrolytes and fluid balance is essential to detect these complications early.

Patients with untreated metabolic alkalosis, severe renal impairment that limits bicarbonate excretion, or uncontrolled heart failure with risk of fluid overload should generally avoid this therapy. Contra‑indications are determined by the treating physician based on individual clinical assessment.